Gilead officer sells 28,000 shares, exercises options
Gilead Sciences Chief Comm & Corp Aff Officer Johanna Mercier reported option exercises and share sales.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Gilead Sciences Chief Comm & Corp Aff Officer Johanna Mercier reported option exercises and share sales. On May 15, 2026, she exercised 25,000 non-qualified stock options at an exercise price of $66.64 per share and acquired the same number of common shares.
That day she also completed open-market sales totaling 28,000 shares of Gilead common stock in multiple trades at prices ranging from about $129.66 to $132.78 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025. Following these transactions, she directly holds 125,779 common shares and retains 23,110 stock options with a $66.64 exercise price expiring on July 24, 2029.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
6 txns
Insider
Mercier Johanna
Role
Chief Comm & Corp Aff Officer
Sold
28,000 shs ($3.68M)
Approx. gross sale proceeds
$3.68M
Approx. exercise cost
$1.67M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-qualified Stock Option (Right to Buy) | 25,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 25,000 | $66.64 | $1.67M |
| Sale | Common Stock | 7,749 | $130.2915 | $1.01M |
| Sale | Common Stock | 11,177 | $131.1917 | $1.47M |
| Sale | Common Stock | 8,374 | $132.2324 | $1.11M |
| Sale | Common Stock | 700 | $132.7514 | $93K |
Holdings After Transaction:
Non-qualified Stock Option (Right to Buy) — 23,110 contracts (Direct);
Common Stock — 125,779 shares (Direct)
Footnotes (6)
- F1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.
- F2. Sale prices for the transactions reported range from $129.66 to $130.63. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
- F3. Sale prices for the transactions reported range from $130.67 to $131.505. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
- F4. Sale prices for the transactions reported range from $131.71 to $132.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
- F5. Sale prices for the transactions reported range from $132.74 to $132.78. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
- F6. The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
Key Figures
Shares sold: 28,000 shares
Options exercised: 25,000 shares
Exercise price: $66.64 per share
+4 more
7 metrics
Shares sold
28,000 shares
Total open-market sales on May 15, 2026
Options exercised
25,000 shares
Non-qualified stock options converted to common stock
Exercise price
$66.64 per share
Non-qualified stock option exercise price
Sale price range
$129.66–$132.78 per share
Price ranges from sale footnotes F2–F5
Shares held after
125,779 shares
Direct common stock holdings after final sale
Remaining options
23,110 options
Non-qualified stock options remaining after 25,000 exercised
Option expiration
July 24, 2029
Expiration date of non-qualified stock option grant
Key Terms
Rule 10b5-1 trading plan, Non-qualified Stock Option (Right to Buy), open-market sale, Exercise or conversion of derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Non-qualified Stock Option (Right to Buy) financial
"security_title: "Non-qualified Stock Option (Right to Buy)" for the derivative transaction."
open-market sale financial
"transaction_action: "open-market sale" with transaction code "S" for common stock."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Exercise or conversion of derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security" for code "M"."
four-year vesting schedule financial
"The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Gilead (GILD) executive Johanna Mercier report in this Form 4?
Johanna Mercier reported exercising 25,000 stock options and selling 28,000 Gilead common shares. The transactions occurred on May 15, 2026, and involved open-market sales executed under a pre-arranged Rule 10b5-1 trading plan adopted earlier in February 2025.
What options did Johanna Mercier exercise in Gilead (GILD) stock?
She exercised 25,000 non-qualified stock options to buy Gilead common stock at an exercise price of $66.64 per share. These options are part of an award with a four-year vesting schedule and an expiration date of July 24, 2029.
What Gilead (GILD) stock options does Johanna Mercier still hold?
Following the 25,000-option exercise, she retains 23,110 non-qualified stock options. These options carry a $66.64 exercise price and have an expiration date of July 24, 2029, according to the derivative transaction details included in the Form 4 data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
